Please assess the completion status of the following clinical trial:

Trial Title: DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically or cytologically proven adenocarcinoma of the prostate~* Documented metastatic prostate adenocarcinoma~* Documented progression while on androgen ablation therapy detected by rising prostate specific antigen (PSA) and/or imaging~* Age \>= 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status \<= 2~* Adequate hematologic, renal and hepatic function~* Life expectancy \>= 3 months~Exclusion Criteria:~* Prior chemotherapy, except estramustine~* Prior chemotherapy with docetaxel~* Prior isotope therapy (e.g., strontium-89, samarium-153, etc.)~* One or more contraindications to the use of corticosteroids~* History of cancer-related hypercalcemia

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).